Related Experiment Video

Updated: Mar 26, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?

Begoña Quintana-Villamandos1, Emilio Delgado-Baeza2

  • 1Departamento de Anestesiología, Hospital Gregorio Marañón, Madrid, Spain; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Medical Hypotheses
|January 31, 2016
PubMed

Insights

Short-term beta-blocker treatment with esmolol can reverse hypertensive left ventricular hypertrophy (LVH) by improving nitric oxide (NO) bioavailability and antioxidant status, targeting the ADMA/DDAH/NO pathway for early cardiovascular disease risk reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Physiology

Background:

  • Hypertensive left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular disease, often requiring long-term antihypertensive therapy for regression.
  • Asymmetrical dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, is implicated in LVH development and cardiovascular risk.
  • The ADMA/DDAH/NO pathway plays a crucial role in modulating left ventricular mass and is influenced by oxidative stress, which is elevated in LVH patients.

Purpose of the Study:

  • To investigate the potential of short-term esmolol treatment to induce early regression of LVH.
  • To explore the role of the ADMA/DDAH/NO pathway in esmolol-mediated LVH regression.
  • To assess the impact of esmolol on NO bioavailability and oxidative stress in the context of LVH.

Main Methods:

  • Preclinical study utilizing spontaneously hypertensive rats.
  • Short-term (48-hour) administration of esmolol.
  • Assessment of left ventricular mass, NO bioavailability, and plasma antioxidant status.

Main Results:

  • Short-term esmolol treatment effectively reversed early LVH in spontaneously hypertensive rats.
  • Esmolol administration led to increased NO bioavailability.
  • The treatment also improved the antioxidant status in plasma.

Conclusions:

  • The ADMA/DDAH/NO pathway is a potential mechanism for early LVH regression induced by short-term esmolol treatment.
  • Esmolol demonstrates promise for rapid therapeutic intervention in hypertensive cardiovascular disease.
  • Targeting NO bioavailability and oxidative stress may be key strategies for managing LVH.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.7K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

7.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
548
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
517
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
744